Eli Lilly Q3 Earnings Preview: Key Factors to Watch Amid Mixed Performance
ByAinvest
Monday, Oct 27, 2025 11:29 am ET1min read
LLY--
Eli Lilly and Company (LLY) is set to report Q3 2025 earnings on Oct. 30. The Zacks Consensus Estimate is pegged at $16.01 billion in sales and $6.02 per share in earnings. Earnings estimates for 2025 have declined from $23.15 per share to $22.73 per share. The company has a mixed performance, exceeding earnings expectations in two of the trailing four quarters while missing in the remaining two. Lilly has an Earnings ESP of -0.66% and a Zacks Rank #3 (Hold). The key drivers of Lilly's top-line growth are expected to be its popular GLP-1 drugs, Mounjaro and Zepbound, driven by high demand trends.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet